The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies.

Market Growth Overview

• 2023 to 2024 Growth: The visceral pain treatment market is set to grow from $12.87 billion in 2023 to $13.84 billion in 2024, reflecting a compound annual growth rate (CAGR) of 7.6%.
• Historic Growth Drivers: Aging population, increased chronic diseases, advances in medical research, expanded healthcare infrastructure, and rising awareness and diagnosis rates have driven past growth.

Future Market Prospects

• 2024 to 2028 Growth: The market size is projected to reach $17.70 billion by 2028, with a CAGR of 6.3%.
• Future Growth Drivers: Technological innovations, growing demand for non-invasive treatments, emerging markets, personalized medicine, and digital health solutions will propel growth.

View More On The Visceral Pain Market Report 2024 – https://www.thebusinessresearchcompany.com/report/visceral-pain-global-market-report

Key Market Trends

• Multimodal Pain Management: A shift towards combining various pain management techniques.
• Alternative Therapies: Increased emphasis on non-traditional pain relief methods.
• Targeted Therapies: Rise of treatments aimed at specific types of pain.
• Telemedicine: Growing role in managing pain remotely.
• Artificial Intelligence: Integration in pain assessment and treatment planning.

Rising Demand for Analgesics

• Buprenorphine Prescriptions: Significant increase in buprenorphine prescriptions, from 16,011,239 in 2020 to 16,105,318 in 2021, as documented by the CDC.
• Role of Analgesics: These medications manage visceral pain by targeting the nervous system and modulating pain signals from internal organs.

Major Market Players

• Notable Companies: Walgreens Boots Alliance Inc., Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Mylan N.V., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Dr. Reddy’s Laboratories Ltd., Endo International PLC, Grünenthal GmbH, Glenmark Pharmaceuticals Limited, Hisamitsu Pharmaceutical Co. Ltd., Chromocell Corporation, Addex Therapeutics Ltd.

Innovative Treatments: NHE3 Inhibitors

• NHE3 Inhibitor Drug: Ardelyx launched IBSRELA in April 2022, targeting irritable bowel syndrome with constipation (IBS-C).
• Mechanism: NHE3 inhibitors reduce abdominal pain by decreasing visceral hypersensitivity and intestinal permeability.

Strategic Acquisitions

• Jazz Pharmaceuticals and GW Pharmaceuticals: In February 2021, Jazz Pharmaceuticals acquired GW Pharmaceuticals for $7.2 billion.
• Impact: The acquisition expanded Jazz’s portfolio with GW’s cannabinoid products, including Epidiolex, approved for chronic visceral pain syndromes.

Market Segmentation

• By Drug Class: Calcium Channel Blockers, NSAIDs, Other Drug Classes
• By Indications: Interstitial Cystitis, Crohn’s, Irritable Bowel, Chronic Prostatitis, Other Indications
• By End Users: Hospitals, Homecare, Specialty Clinics, Other End Users

Regional Insights

• North America: The largest region in the visceral pain market in 2023.

The visceral pain treatment market is poised for significant growth, driven by technological advancements, increased demand for non-invasive treatments, and strategic acquisitions by major pharmaceutical companies. The integration of digital health solutions and artificial intelligence will further enhance pain management and patient outcomes in the coming years.

Request A Sample Of The Global Visceral Pain Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=13950&type=smp